{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\n In a study aimed at developing a prognostic signature for patients with advanced renal cell carcinoma (RCC), ITPKB‐AS1 was identified among nine key long non‐coding RNAs (lncRNAs) that collectively correlate with overall survival in patients with stage IV and histological grade G4 RCC."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": " Pathway enrichment analysis indicated that these lncRNAs, including ITPKB‐AS1, may contribute to key cellular processes such as cell division, regulation of the cell cycle, DNA damage response, and modulation of cytokine levels, suggesting their potential roles in tumor progression and response to treatment."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": " Consequently, ITPKB‐AS1, as part of this lncRNA signature, holds promise not only as a prognostic biomarker, but also as a possible guiding factor in tailoring treatment strategies for patients with high-stage and high-grade RCC."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": "\n "}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Ning Li, Haiying Zhang, Keyao Hu, et al. "}, {"type": "b", "children": [{"type": "t", "text": "A novel long non-coding RNA-based prognostic signature for renal cell carcinoma patients with stage IV and histological grade G4."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Bioengineered (2021)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1080/21655979.2021.1971022"}], "href": "https://doi.org/10.1080/21655979.2021.1971022"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "34499010"}], "href": "https://pubmed.ncbi.nlm.nih.gov/34499010"}]}]}]}